Why the study?
Does evolocumab improve coronary plaque characteristics and pericoronary adipose tissue density in patients with type 2 diabetes mellitus?
Does evolocumab improve coronary plaque characteristics and pericoronary adipose tissue density in patients with type 2 diabetes mellitus?
Evolocumab favorably modifies coronary plaque composition and reduces pericoronary inflammation (measured by PCAT density) in patients with type 2 diabetes, potentially mediated by Lp(a) reduction.
Answers are grounded in this paper and cite their sources.
May support evolocumab for plaque modification in T2DM; hypothesis-generating for Lp(a) mediation, needing RCTs.
In patients with T2DM, evolocumab is an effective therapy to decrease noncalcified plaque volume necrotic volume, and increase calcified plaque volume. Furthermore, evolocumab could attenuate PCAT density, at least in part, via the reduction of lipoprotein(a).
No takes yet. Share an insight, caveat, or question.
Yu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: